Objectives: Using synchronous cultures of Plasmodium falciparum malaria, the stage sensitivity of the parasite to OZ277 (RBx-11160), the first fully synthetic antimalarial peroxide that has entered Phase II clinical trials, was investigated in vitro over a concentration range of 1· to 100· the IC 50 . Secondly, partitioning of OZ277 into P. falciparum-infected red blood cells (RBCs) and uninfected RBCs was studied in vitro by measuring its distribution between RBCs and plasma (R/P).
Introduction
The sesquiterpene lactone artemisinin was isolated by Chinese scientists in 1971 by extraction of Artemisia annua (the sweet wormwood plant) into diethyl ether at low temperature. The 'active principle' was subsequently shown to cure mice infected with Plasmodium berghei. In 1972, further work culminated in the isolation of a crystalline compound that was named qinghaosu, or artemisinin, after the generic name of the plant 1 and demonstrated that its peroxide bond is essential for antimalarial activity. 2, 3 Artemisinin can be converted into its semisynthetic derivatives, artemether and artesunate, which are more active than the parent molecule. 4 However, the isolation of artemisinin from the plant makes it and its semisynthetic derivatives several fold more expensive than the relatively inexpensive standard antimalarials chloroquine and pyrimethamine/sulfadoxine. The first total synthesis (13 steps, 5% overall yield) of artemisinin was reported in 1983. 5 Since then, several groups have reported different pathways for the synthesis of artemisinin, but all require numerous steps and have low yields. [6] [7] [8] Thus, none of these complex syntheses provides a viable method for large-scale production of the molecule. 9 Although the semisynthetic artemisinins (in combination with longer acting antimalarials) are currently the drugs of choice to treat multidrug-resistant malaria, access to these agents in disease endemic countries has been limited mainly due to their cost and availability. Recently, Vennerstrom et al. 10 published the discovery of a new synthetic peroxide antimalarial called OZ277 (RBx-11160). OZ277, currently in Phase II clinical trials, exhibits structural simplicity, an economically feasible and scalable synthesis, superior antimalarial activity and a better biopharmaceutical profile than artemisinin and its semisynthetic derivatives. Furthermore, OZ277 is fully synthetic and structurally different from the artemisinin drug class. Artemisinins contain a six-membered 1,2,4-trioxane heterocycle whereas OZ277 contains a five-membered 1,2,4-trioxolane, more commonly known as a secondary ozonide. The present study describes for the first time the pharmacodynamic effects of this novel drug development candidate on Plasmodium falciparum cultures by assessing its stage specificity and rate of action in comparison with three standard antimalarial drugs at clinically relevant concentrations. The partitioning of OZ277 into infected and non-infected red blood cells (RBCs) was also examined.
Materials and methods

Chemicals and materials
Chemicals and materials were from Sigma, Perkin-Elmer and GIBCO Invitrogen except for OZ277 tosylate (J. L. Vennerstrom, Nebraska, USA), artemether (Kunming Pharmaceuticals Corporation, China), pyrimethamine (Roche, Basel, Switzerland) and H]hypoxanthine (Amersham Bioscience, UK). Antimalarial compounds were dissolved in dimethylsulfoxide (DMSO) at 10 mg/mL. The stock solutions were kept at 4 C for not more than 6 months. Two [ 14 C]OZ277 hydrogen maleate salts (508 g/mol) were used-one was labelled in the adamantane ring (OZ277[L], Moravek Biochemicals; specific activity: 31 mCi/mmol) and the other in the side chain (OZ277[R], a gift from F. Hoffmann-La Roche Ltd; specific activity: 42 mCi/mmol, Figure 1 ). The compounds were prepared as 10 mg/mL stock solutions in toluene and stored at -80 C.
Parasite cultivation
NF54, a drug-sensitive isolate of P. falciparum, was maintained in 10 cm Petri dishes and cultured by standard methods 11 in an atmosphere of 93% N 2 , 4% CO 2 , 3% O 2 at 37 C. The culture medium was RPMI 1640 10.44 g/L, supplemented with Hepes 5.94 g/L, Albumax II 5 g/L, hypoxanthine 50 mg/L, sodium bicarbonate 2.1 g/L and neomycin 100 mg/L. When required, parasites were synchronized twice with 5% D-sorbitol. 12 The second treatment was 7-8 h after the first. This procedure provided in most cases a parasite culture containing ‡80% young trophozoites (20 h old). Initial parasitaemias varied between 3% and 11% in all studies.
Growth inhibition assay and washing procedure P. falciparum growth was assessed by measuring incorporation of the nucleic acid precursor [ 3 H]hypoxanthine. 13 IC 50 values were found to be 0.91 -0.12 ng/mL for OZ277, 1.2 -0.1 ng/mL for artemether, 5.1 -0.8 ng/mL for chloroquine 10 and 5.6 -0.5 ng/mL for pyrimethamine. Synchronized cultures of young NF54 trophozoites (20 h) with parasite counts of 0.15% and a haematocrit of 5% were divided into three 10 cm Petri dishes. Two dishes were further incubated for 16 or 32 h at 37 C for maturation into early schizonts (36 h) or early ring stages (4 h). The third dish with the early trophozoites was used immediately for exposure for a 1, 6, 12 or 24 h period to the following four antimalarial compounds: OZ277 and artemether (final concentrations 100, 13, 1.6 ng/mL), chloroquine and pyrimethamine (final concentrations 500, 63, 8 ng/mL). After the respective incubation times for the parasite-compound mixture, the plates were washed four times resulting in a 1280-fold dilution of the free compound. After another incubation period of 24 h at 37 C in the atmosphere described above and in the presence of [ 3 H]hypoxanthine, the plates were frozen at -20 C. For the IC 50 determination, plates were thawed and harvested with a Betaplate cell harvester (1295-004 Betaplate; Wallac Perkin-Elmer) onto glass filters. The dried filters were inserted into a plastic foil with 10 mL of scintillation fluid and counted in a Betaplate liquid scintillation counter (1205 Betaplate; Wallac Perkin-Elmer). The results of each well were recorded as counts per min and expressed as a percentage of the untreated controls. Suspensions of uninfected erythrocytes were used for background subtraction. For morphological analysis of antimalarial action, synchronized cultures were treated with compounds (100· IC 50 ) in 10 cm Petri dishes. Light-microscopic evaluation of Giemsastained thin blood smears was performed every hour by using an oil-immersion lens (1000·). Changes in parasite morphology were compared with compound-free control cultures.
Time-course of uptake into RBCs
Samples containing 230 mL of infected erythrocytes and 470 mL of plasma at a final OZ277 concentration of 77 ng/mL (as either the R or L radiolabelled material, Figure 1 ) were incubated in a water bath at 37 C for various time periods ranging from 10 min up to 3 h. At the end of the incubation period, tubes were centrifuged at 600 g for 5 min to form RBC pellets; 230 mL of each supernatant was transferred to a new tube. The rest of the supernatant was discarded and the pellets (230 mL) were kept for further processing. In addition, all experiments included the following two controls: (i) 700 mL of plasma (no RBCs) containing a final [
14 C]OZ277 concentration of 77 ng/mL was incubated for 20 min and 2 h; and (ii) a mixture OZ277 stage specificity and partitioning in malaria of 470 mL of plasma (containing no [ 14 C]OZ277) and 230 mL of uninfected RBCs was incubated for 1 h. From tube (i) 230 mL of the drug mixture and from the background-control (ii) 230 mL of the supernatant were also transferred to new tubes. Then, to each of the tubes containing the various controls, test supernatants and pellets, 1 mL of a 50:50 mixture of isopropanol and soluene-350 was added, followed by incubation at 60 C for 1 h in a water bath. The samples were then bleached with 3.2 mL of 30% hydrogen peroxide and again incubated at 60 C for 30 min in a water bath. Finally, 15 mL of OptiPhase 'Super Mix' scintillation cocktail was added. The contents of the tubes were mixed, 4 mL transferred to scintillation vials and counted after 3-4 h using a liquid scintillation counter (1450 Microbeta plus; Wallac Perkin-Elmer). To confirm mass balance and the absence of a significant contribution of extracellular fluid on the measured counts for the pellet, the counts for the total test-vial sample volume were calculated from the measured counts for the plasma supernatant and the RBC pellet. This value was then compared with the total counts for the plasma control (i). Results were not considered if the measured counts of OZ277 for the plasma control (i) differed by more than 10% from that calculated for the test-vial (containing RBCs and plasma). For the vast majority of the experiments, total counts for the control and test vials differed by <10%. Results of the background-control (ii) were used for background subtraction. Where uptake ratios (R/P; i.e. gradient between RBCs and plasma) were calculated, they represented the calculated ratio of radioactivity in 230 mL of 100% infected RBCs to the same volume of plasma collected at the end of incubation. The uptake into non-infected RBCs was accounted for by using the following equation:
where dpm I = dpm in 230 mL of 100% infected erythrocytes, dpm R = dpm in 230 mL of infected cell pellet (i.e. containing infected and non-infected RBCs), dpm N = dpm in 230 mL of non-infected cell pellet (i.e. containing only non-infected RBCs) and x = % parasitaemia. R/P was then calculated by dividing dpm I by dpm in 230 mL of plasma collected at the end of incubation.
Effect of compound concentration on RBC uptake
Infected or uninfected erythrocytes (230 mL) were mixed with 420 mL of plasma and 50 mL of [ 14 C]OZ277 [L] in plasma at concentrations ranging from 40 to 64 000 ng/mL. All samples, including controls (i) and (ii), were incubated for 1 h at 37 C. Extraction of the samples was performed as described above.
Results
Pharmacodynamic studies
Stage-specific effects of 1, 6, 12 or 24 h of compound exposure were investigated using the hypoxanthine incorporation assay with highly synchronous cultures of P. falciparum NF54 over a concentration range of 1· to 100· the IC 50 of the four compounds OZ277, artemether, chloroquine and pyrimethamine. The washing procedure following the respective incubation periods was performed in a way that the unbound compound was diluted at least 1000-fold. Using this procedure, the viability of parasites during the subsequent [ 3 H]hypoxanthine-incubation period of 24 h could be assessed in the absence of unbound compound. Parasitic stages evaluated were young rings (4 h), young trophozoites (20 h) and young schizonts (36 h). Figure 2 shows parasite growth plotted against incubation time for three selected compound concentrations: 1· IC 50 , 10· IC 50 and 100· IC 50 . After 1 h of exposure to OZ277, artemether or chloroquine at the highest concentration (100· the IC 50 ), ring forms were slightly more resistant to the three compounds than trophozoites and schizonts. From 6 up to 24 h of compound incubation, all stages reacted similarly, with strong inhibition (£6% growth) at 100· IC 50. Interestingly, at the lowest OZ277 concentration (1· IC 50 ), schizonts underwent a steady decrease of growth after 6 h, then an increase at 12 h and a decrease at 24 h. The marked increase in growth after 12 h was repeated and confirmed in three independent experiments. The growth inhibition of ring and trophozoite populations remained relatively stable from 6 h onwards.
At the lowest artemether concentration tested (1· IC 50 ), a minimal inhibitory effect was observed against all parasite forms over the entire period investigated, whereas at the lowest chloroquine concentration a relatively linear decrease of growth within 24 h was noted for all stages. Stage-specific analysis with pyrimethamine demonstrated that growth of the ring and trophozoite stages was not affected, even after 24 h at the highest concentration. The only pyrimethamine-sensitive parasite form was the schizont. Growth inhibition of 20-40% was observed after 6 and 12 h at medium to high pyrimethamine concentrations. The 24 h incubation period clearly resulted in the strongest schizont growth inhibition, even at the lowest concentration. To determine the morphological changes of P. falciparum by light microscopy, synchronous cultures of NF54 were exposed to OZ277, artemether, chloroquine and pyrimethamine, respectively, at fixed compound concentrations of 100· IC 50 . Thin, Giemsa-stained blood smears were taken hourly from 1 to 9 h and after 24 h. The morphological changes observed were very similar for OZ277, artemether and chloroquine. In young ring forms, the nucleus was most affected in the first 1-2 h. In schizont and trophozoite forms, the first changes were observed usually after 1 and 3 h, respectively. Morphology changes were clumping of crystals, a paler disorganized cytoplasm and vacuolation (data not shown). In contrast to OZ277, artemether and chloroquine, most of the pyrimethamine-treated ring and trophozoite stages developed further to their next stage, even up to the end of the monitoring period (24 h). Only the cytoplasm of schizonts became paler and crystals started to clump (8-9 h) until the parasites actually stopped developing or disintegrated (24 h). Table 1 shows the accumulation of [
Time-course of uptake into RBCs
14 C]OZ277[L] by uninfected erythrocytes or erythrocytes infected with young and mature parasites over a time period of 10 min up to 3 h at a compound concentration of 77 ng/mL. Mature parasites accumulated the compound more quickly and at a higher average ratio (30 min, R/P = 214) than ring forms (2 h, R/P = 53). Based on the R/P ratio at 3 h, concentrations of the radiolabelled compound in infected RBCs of both mature and young parasite stages declined to about half the maximum value. Under these same conditions, uninfected erythrocytes showed an uptake ratio of about 1.5, which was maintained throughout the 3 h incubation period. Figure 3 
Effect of different compound concentrations on RBC uptake
The results from incubations conducted at concentrations of 38-64 000 ng/mL of radiolabelled OZ277[L] and analysed at a single time-point of 1 h showed that at higher concentrations the uptake ratios reached a constant value of 23 ( Figure 4 ). Uninfected RBCs had a steady uptake ratio of about 2 (data not shown) over this same incubation period.
Discussion
Relatively little is known about the rate of action and selective toxicity of antimalarials against the morphologically distinguishable different blood stages of P. falciparum.
14 These pharmacodynamic factors may be important determinants of immediate antimalarial drug efficacy in severe malaria and could provide important clues about the mechanism of action. Another reason for the selective toxicity of antimalarials such as chloroquine and the artemisinin family of drugs can be attributed to the increased accumulation in parasitized RBCs. [15] [16] [17] [18] Given these considerations, we assessed in vitro the pharmacodynamic properties and the partitioning of OZ277, the first fully synthetic antimalarial peroxide that has entered Phase II clinical trials, in cultures of P. falciparum.
Pharmacodynamic studies indicated that OZ277, artemether and chloroquine influence growth of all parasite stages in a similar way (Figure 2 ). An exposure time of ‡1 h at a high compound concentration range was sufficient to achieve substantial growth inhibition and morphological changes of all parasite stages. However, at a relatively low compound concentration of 1· IC 50 , parasite growth was reduced only marginally, and after 24 h, chloroquine showed the strongest growth reduction effect followed by OZ277 and artemether. These observations are consistent with microscopic studies performed by Alin et al. 19 and Ye et al. 20 , who reported that an artemisinin concentration of 4 ng/mL for 48 h had no appreciable effect on the parasites. In related studies, Ter Kuile et al. 21 measured the antimalarial effects of artemisinin, artelinic acid and other compounds by inhibition of incorporation of [ Variation of individual values was low except for OZ277 ring stage at 1 h ( -65% at 13 ng/mL and -46% at 1.6 ng/mL) and pyrimethamine ring stage at 1 h (-31% at 63 ng/mL and -55% at 8 ng/mL). Pyrimethamine 6 h experiment was only conducted once.
OZ277 stage specificity and partitioning in malaria artelinic acid than were the young ring stages. They also reported that the inhibition was dose-dependent. Our results with artemether at the 1 h time-point (1· up to 100· IC 50 ) (Figure 2 ) are in good agreement with these reports. Studies performed by Geary et al. 22 using the [ 3 H]hypoxanthine assay also showed a similar stage specificity for artemisinin. This is encouraging, especially since a direct comparison of our results with those of Ter Kuile et al. 21 is difficult, because of the different methodologies used in the two studies. Ter Kuile et al. 21 used a higher parasitaemia of 0.4-0.8% and a two cycle as well as a same cycle experiment, factors that could have altered parasite growth, and thereby efficacy profiles. Our data are also consistent with data reported by Skinner et al. 23 and Alin et al. 19 Skinner et al. showed that an IC 90 concentration of dihydroartemisinin (DHA) is rapidly effective against all three stages of the parasite. In these experiments, a [ 3 H]hypoxanthine assay was used to show that young trophozoites (20-24 h) and young schizonts (36 h) achieve 95% growth inhibition after 2 h of incubation. They also observed ring forms to be more resistant, achieving 95% growth inhibition only after 6 h. Surprisingly, in this same work, the group demonstrated that artemether and artemisinin, unlike DHA, showed relatively little activity against trophozoites, while a more DHA-like effect was found against the other two forms. The authors explained the discrepancy of their trophozoite result with the relatively low compound concentration (IC 90 ) used in their experiments. Alin et al. 19 performed microscopic counting experiments with unsynchronized parasites that had been incubated for 1 h with an artemisinin concentration range of 40-4000 ng/mL. They reported that 48 h after removal of the compound, the predominant parasite stage that remained viable in culture was rings. In contrast, after ‡6 h in the presence of compound, the remaining viable stages were evenly distributed, suggesting that £6 h is enough to affect all stages to the same extent.
In terms of chloroquine, our stage dependency data were in good agreement with two studies using similar techniques. 21, 24 Both groups reported that trophozoite and schizont stages were considerably more sensitive to the compound. Pyrimethamine is the only compound that was found to be strongly stage specific for young schizonts (Figure 2 ). However, this observation was The initial concentration of the drug was 77 ng/mL. R/P is the uptake ratio obtained from the disintegrations per minute (dpm) in 230 mL of pure parasitized RBCs (correction made for 100% parasitaemia) divided by the dpm in 230 mL of plasma from the same tube. not unexpected, since similar data have been published previously by Dieckmann and Jung. 25 These authors showed that ring and trophozoite stages exposed to 10 nM (= 2.5 ng/mL) pyrimethamine for 6 h grew normally after removal of the compound, which is consistent with our observations for these parasite stages. Of particular interest is that ring forms and trophozoites were resistant to the compound up to the extreme conditions tested (24 h at 500 ng/mL or 100· IC 50 ). Young schizonts, which had been exposed to 100· IC 50 concentrations of pyrimethamine for 12 h, still grew to about 60%. However, a 24 h incubation period resulted in quite strong growth inhibition, even at relatively low pyrimethamine concentrations. Therefore, a long pyrimethamine exposure time seems to be more critical for schizont growth than a high compound concentration. This, and the pronounced stage specificity for schizonts, distinguishes pyrimethamine from the faster acting compounds OZ277, artemether and chloroquine.
A feature of the specific activity of artemether and chloroquine is assumed to be their enrichment in malaria-infected RBCs. Vyas Time-course experiments performed with OZ277 radiolabelled either in the adamantane ring (OZ277[L]) or in the right side chain (OZ277[R]) showed that after 10 min, young ring forms take up comparable amounts of both molecules (Figure 3) . However, after 10 min the concentration of the [R] molecules in the infected RBCs decreased steadily, whereas the [L] molecules accumulated continuously, reaching their maximum after 2 h. This data supports the mechanism of action of OZ277 as proposed by Vennerstrom et al. 10 in that carbon-centred radicals form predominantly on the adamantane ring. Ultimately, such adamantane radicals could alkylate parasite proteins, releasing the remaining unlabelled cleavage product for partitioning back into the supernatant. The fate of such products is unknown and will be further examined in subsequent experiments designed to assess the partitioning behaviour in a more comprehensive manner. Further studies to explore these processes will utilize specific analytical methods in order to characterize the nature of the species present within the erythrocyte and the supernatant.
Similar to DHA and chloroquine, 16, 26 the maximum uptake of OZ277 into infected RBCs was reached faster with mature parasites (30 min) than with young ring stages (2 h) ( Table 1) . This result corresponds to our pharmacodynamic observations where after a 1 h compound exposure, OZ277 and artemether were more effective against more mature parasite stages (Figure 2 ). However, after having reached the maximum uptake, it can only be speculated as to why a steady-state phase was not observed with [ (Figure 3) . The relatively fast decrease in the R/P value observed with both radioactive OZ277 variants might be an indication of how rapidly the ring forms lose their viability, which in this specific experiment would be after the 2 h time-point. This observation is clearly different from the results reported for 16 where using a comparable drug concentration, a stable R/P equilibrium could be observed for 20 h.
In summary, the present study describes a significant accumulation of radiolabelled OZ277, a novel peroxide-based compound, in P. falciparum-infected RBCs. Similar stage-specific profiles were found for OZ277, artemether and chloroquine. The latter drugs are known to prevent sequestration in malaria patients significantly by attenuating the growth of young, asexual parasite forms.
14 Since in onset and recrudescence experiments using the P. berghei murine model, OZ277 has been shown to clear parasitaemia rapidly to below quantifiable limits, 10 the hopes are high that OZ277 will also show similar in vivo pharmacodynamics in malaria patients. Studies of this nature provide further understanding of the relationship between drug concentration and antimalarial effect which may ultimately help to optimize the assessment of antimalarial efficacy and the design of treatment regimens for malaria. Further research into the mechanisms responsible for uptake of OZ277 (and other antimalarials) into infected erythrocytes will be valuable in further defining its pharmacodynamic activity.
